About Rheogene
Rheogene is a Healthcare company based in Norristown (United States) founded in 2003, and was acquired by UPMC in February 2004. Gene-based therapeutic products are developed using modulation platforms. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Rheogene was founded in 2003 and is headquartered in Norristown, United States. Operations focus on biotechnology, specifically the development of gene-based therapeutic products. The RheoSwitch therapeutic system and direct recombinase platform are utilized to modulate gene expression, supported by the Ultravector system. Applications include cellular and gene therapies, enhanced protein expression, and genomics research. Services are provided through these proprietary technologies.
- Headquarters Norristown, United States
- Stage Acquired
- SectorsHealthcare
- Website rheogene.com
- Acquired by UPMC (Feb 2004)
Investors in Rheogene
Rheogene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include UPMC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multispecialty hospitals are operated as a nationwide chain. | 1986 | upmc.com | United States |
Investor details for Rheogene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Rheogene
2 dated milestones of Rheogene across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Rheogene is founded.
- Exit Acquired by UPMC.
Competitors of Rheogene
Rheogene has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Rheogene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Rheogene (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Rheogene
Rheogene was founded in 2003.
Rheogene is headquartered in Norristown, United States. It is registered at Norristown, Pennsylvania, United States.
Rheogene was founded in 2003 and is headquartered in Norristown, United States. Operations focus on biotechnology, specifically the development of gene-based therapeutic products. The RheoSwitch therapeutic system and direct recombinase platform are utilized to modulate gene expression, supported by the Ultravector system. Applications include cellular and gene therapies, enhanced protein expression, and genomics research. Services are provided through these proprietary technologies.
Rheogene's top competitors include BridgeBio, Forge Biologics and Insitro.
Rheogene has 1 investor. Key investors include UPMC.
Yes. Rheogene was acquired by UPMC in February 2004.